Empire State Index Comes in Below Expectations
Pre-market futures are climbing this morning, filling in the holes left Friday as the Israeli attacks on Iran saw oil prices spike and questions abound on impacts to the global economy. As we've seen over the weekend, while the two countries trade missile strikes, we haven't seen the Strait of Hormuz affected as of yet, nor any other major developments on the global stage.
We're at this hour coming off peak levels of +295 points on the blue-chip Dow, +45 points on the S&P 500 and +205 points on the tech-heavy Nasdaq. The small-cap Russell 2000 was up +25 points in pre-market trading. Friday saw the Dow sink by more than -760 points, the Nasdaq -255 and the S&P 500 found its way back under 6K, -68 points.
The Fed meets for its two-day Federal Open Market Committee (FOMC) meeting, starting tomorrow and concluding Wednesday. It is widely expected there will be no change to the Fed funds rate from the 4.25-4.50% range we've been in since December of last year. It will be interesting to see how the Fed reacts to a cooling — but not unraveling — labor market, as well as inflation metrics remaining north of their +2.0% target.
The manufacturing survey known as the Empire State Index is out this morning for the month of June, with the headline number coming 10 points lower than expected: -16.0. This follows an unrevised -9.2 the previous month, and extends the streak of negative manufacturing production for the state of New York to four months. Seven of the past 12 months have been negative, as well.
After today's close, we will see fiscal Q2 results from Miami-based homebuilder Lennar Homes LEN. Comps from the year-ago quarter are expected to be tough: earnings are projected to come in -42% and revenues -6% for the quarter. The company carries a Zacks Rank #4 (Sell) into this afternoon's report.
We have a pretty full plate for economic reportage this week, especially seeing we're shortened by Thursday's Juneteenth holiday, when the markets are closed. Thus, Weekly Jobless Claims, normally reserved for Thursday morning, will come out Wednesday ahead of the bell, instead.
Otherwise, we'll see Retail Sales, Imports & Exports, Industrial Production & Capacity Utilization — all for May. Also, Business Inventories for April and Homebuilder Confidence for June. Housing Starts & Building Permits for May also are expected, along with June Philly Fed numbers and U.S. Leading Economic Indicators (LEI) for May.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Lennar Corporation (LEN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Amazon (AMZN) Commits $13B to AI Data Centers in Australia — Its Largest Tech Investment Yet
Inc. (NASDAQ:AMZN) is one of the 12 AI Stocks Every Investor Should Be Watching. On June 14, the company disclosed in a blog post that it will invest A$20 billion ($12.97 billion) from 2025 to 2029 to expand, operate, and maintain its data center infrastructure in Australia to boost the nation's artificial intelligence capabilities. The investment, said to be Amazon's largest global technology commitment in the country, will be directed toward new server capacity and support for generative AI workloads. It is also investing in three new solar farms in Victoria and Queensland. 'Amazon Web Services' $20 billion investment in data centres in Australia will set us up for the future, boosting our economy and productivity. This is a huge vote of confidence in the Australian economy.' Inc. (NASDAQ:AMZN) is an American technology company offering e-commerce, cloud computing, and other services, including digital streaming and artificial intelligence solutions. While we acknowledge the potential of AMZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
The Company Anticipates that with this Additional Funding, PolyPid's Runway would be Extended beyond Anticipated U.S. Food and Drug Administration ('FDA') Approval of D-PLEX₁₀₀. The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLEX₁₀₀ Demonstrated a Statistically Significant Reduction in Surgical Site Infections ('SSIs') and Successfully Met the Study's Primary Endpoint and all Key Secondary Endpoints. PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid's runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. The funding was secured through new agreements the Company has entered into with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 7,626,514 ordinary shares, no par value, of the Company originally issued in January 2024 and December 2024. As part of the new agreements, the warrants will be exercised at a price of $3.50 per share. The aggregate gross proceeds from the exercise of the existing warrants are expected to total $26.7 million. In consideration for the immediate exercise of the warrants for cash, the Company will issue 7,626,514 new unregistered warrants to purchase ordinary shares. The new warrants will be exercisable for an aggregate of up to 7,626,514 ordinary shares, at an exercise price of $4.50 per share and will be immediately exercisable upon issuance and for a term of two years from the issuance date. As part of the terms of the financing, it has been agreed that if the holder transfers/sells any of the shares acquired upon exercise of the existing warrants prior to the expiration or exercise of the new warrants, the new warrants shall immediately and automatically terminate and be forfeited with respect to the corresponding number of shares sold, unless such new warrants are concurrently exercised. The transaction is expected to close on or about June 18, 2025, subject to satisfaction of customary closing conditions. PolyPid intends to use the net proceeds from the offering for its new drug application ('NDA') submission, launch preparations, working capital and general corporate purposes. The new warrants described above were offered in a private placement pursuant to under Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act') and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About D-PLEX₁₀₀D-PLEX₁₀₀, PolyPid's lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX₁₀₀ into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. PolyPid recently announced successful topline results from its Phase 3 SHIELD II trial. In this study, D-PLEX₁₀₀ demonstrated a statistically significant reduction in SSIs and successfully met the study's primary endpoint and all key secondary endpoints. About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate, D-PLEX₁₀₀, demonstrated a statistically significant reduction in SSIs and successfully met the primary endpoint and all key secondary endpoints in the SHIELD II Phase 3 clinical trial. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Forward-looking StatementsThis press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expected cash runway, the expected closing date of the warrant inducement transaction, the use of proceeds, potential NDA submission and potential clinical benefits of D-PLEX₁₀₀, including safety and efficacy. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company's Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts: PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578BRitchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Why American Express Stock Bumped Higher on Monday
American Express is giving its Platinum cards an update. Management promised more features and perks, details of which should be provided in the coming months. 10 stocks we like better than American Express › With news of upcoming changes to its most popular product, American Express (NYSE: AXP) was a winner on the stock market as the trading week began. The company's shares increased more than 2% in value on Monday, more than double the 0.9% percentage gain of the S&P 500 (SNPINDEX: ^GSPC). Before market open, AmEx announced a series of major updates to its premium Platinum Card, a bonus-packed card that is its No. 1 product. The catch is, that won't occur right away. AmEx said in a fairly brief press release that more details would be forthcoming in the fall. It did not provide more detail. In fact, detail was quite sparse in the press release. The payment card giant didn't get specific at all regarding changes and adjustments to its popular Member Rewards program. It only went as far as to quote its group president of U.S. consumer services Howard Grosfield as saying, "We're going to take these cards to a new level, not only in what they offer in travel, dining, and lifestyle benefits, but also in how they look and feel, to meet the evolving needs of our customers." AmEx did, however, offer a few clues within its communication. In the travel sphere, it boasted that qualifying card "members" can potentially access more than 1,550 airport lounges throughout the world. More are on the way; the company said it will open its Centurion Lounges in airports located in Newark, New Jersey; Salt Lake City, Utah; and across the Pacific Ocean in Tokyo. It's likely the company will spruce up at least a few existing lounges, too. Management also touted AmEx's continued investment in dining and hotel options, so we can imagine the company boosting these offerings for cardholders as well. The credit card space is becoming ever more competitive, with issuers scrambling to offer more and better perks. This is AmEx's wheelhouse, and as the master of perks, it's comforting to see the company still considers them a priority. Before you buy stock in American Express, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and American Express wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 American Express is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why American Express Stock Bumped Higher on Monday was originally published by The Motley Fool
